Fixed dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill.

Licensed fixed dose combinations include:

Combivir® : Combivir® = AZT + 3TC. The FDA approved it September 26, 1997, making it the thirteenth approved antiretroviral. It is marketed by GlaxoSmithKline.

Trizivir® : Trizivir® = abacavir (ABC) + AZT + 3TC. The FDA approved it November 15, 2000, making it the eighteenth approved antiretroviral drug. It is marketed by GlaxoSmithKline.

Kaletra® : Kaletra® = lopinavir (for its HIV protease enzyme inhibition) with ritonavir included to boost serum levels of lopinavir through inhibition of CYP3A4, a liver enzyme that metabolizes many other substances. The FDA approved it September 15, 2000, making it the seventeenth approved antiretroviral drug. It is the first multi-drug capsule that contains a drug not available individually. It has been demonstrated to be extremely potent and is often used in 'salvage' therapy for patients with some level of drug resistance. Some studies have suggested Kaletra is potent enough to be used as monotherapy and is also suitable for once-daily dosing, although neither is currently recommended. Marketed by Abbott Laboratories, its patent will expire in the United States on 2016-06-26.

Epzicom® : Epzicom® (also Kivexa®) = ABC + 3TC. The FDA approved it August 2, 2004 for once-a-day dosing. It is marketed by GlaxoSmithKline.

Truvada® : Truvada® = emtricitabine + tenofovir. The FDA approved it August 2, 2004 for once-a-day dosing. It is marketed by Gilead Sciences.

HIV/AIDS | Antiretroviral drugs